
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics is facing some setbacks with their Phase 3 asset, eDSP, missing in the Phase 3 NEAT trial for treating a pediatric neurodegenerative disease, A-T. This has caused a downgraded rating to Market Perform from Market Outperform. The company faces risks such as clinical and regulatory uncertainty, as well as potential market share and valuation erosion.
Bears say
Quince Therapeutics is facing several fundamental challenges, including the failure of its lead candidate eDSP in the Phase 3 NEAT trial for A-T, discontinued clinical development of eDSP, a lack of revenue projections, and an uncertain pipeline with a single asset and potential regulatory complexities. Additionally, the company may need to raise additional capital and faces the risks associated with commercializing a drug for a rare disease market. These factors contribute to a negative outlook for Quince's stock.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares